

Abstract

Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer 5 therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.